Krishna Mohan Mallavarapu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Krishna Mohan Mallavarapu has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Subramanyeshwar Rao Thammineedi
Department of Surgical Oncology, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, India
3 shared publications - Deleep Gudipudi
Radiation Oncology,Basavatarakam Indo American Cancer Hospital and Research Institute,Hyderabad,India, India
2 shared publications - Harveen Kaur Gulati
Pathology,Basavatarakam Indo American Cancer Hospital and Research Institute,Hyderabad,India, India
2 shared publications - Kiruthika Subramaniyan
Medical oncology,Basavatarakam Indo American Cancer Hospital and Research Institute,Hyderabad,India, India
2 shared publications - Naga Prasanthi Akkineni
Radiation Oncology,Basavatarakam Indo American Cancer Hospital and Research Institute,Hyderabad,India, India
2 shared publications - R. Rajagopalan Iyer
Surgical Oncology,Basavatarakam Indo American Cancer Hospital and Research Institute,Hyderabad,India, India
2 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7693
Clinical Heterogeneity and Survival Disparities in Leiomyosarcoma: An Exploratory Single-Center Retrospective Observational Study
Background: Leiomyosarcoma (LMS) is a rare aggressive sarcoma with substantial heterogeneity in anatomical presentation, stage, treatment, and survival. We evaluated clinical characteristics, treatment patterns, and survival, with particular emphasis on whether anatomical site independently predicted overall survival (OS). Methods: We retrospectively reviewed 240 adults with histologically confirmed LMS diagnosed between January 2015 and May 2026. OS was calculated from diagnosis to death or last contact, with administrative censoring on 1 July 2026. Kaplan–Meier and Cox proportional-hazards methods were used to evaluate age, sex, anatomical site, histologic grade, and disease stage. Multivariable models adjusted for age, sex, grade, and stage assessed the independent association of anatomical site with OS. Results: Median age was 56 years, and 152 patients (63.3%) were female. Disease was localized in 120 (50.0%), de novo metastatic in 53 (22.1%), recurrent metastatic in 35 (14.6%), and recurrent localized in 12 (5.0%). Median OS was 37.0 months. Localized disease was associated with substantially longer OS than metastatic disease (61.0 vs. 13.0 months; p < 0.001). Grade 3 disease was associated with shorter OS than grade 1/2 disease (25.6 vs. 61.1 months; p < 0.001). In multivariable analyses, metastatic disease remained strongly associated with inferior OS (HR, 5.59–5.94; p < 0.001), as did age ≥ 50 years (HR, 1.86–1.92; p = 0.006–0.004) and grade 3 histology (HR, 1.74–1.92; p = 0.018–0.007). Anatomical site was not independently associated with OS (extremity/trunk vs. non-extremity: HR, 1.60; p = 0.063; non-uterine vs. uterine: HR, 1.23; p = 0.41). Conclusions: Disease stage was the strongest prognostic factor, while older age and grade 3 histology were independently associated with poorer OS. Although extremity/trunk LMS showed better univariable survival, anatomical site was not independently associated with OS after adjustment.
- 4 October 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (19) , 7693
Open AccessClinical Heterogeneity and Survival Disparities in Leiomyosarcoma: An Exploratory Single-Center Retrospective Observational Study
Background: Leiomyosarcoma (LMS) is a rare aggressive sarcoma with substantial heterogeneity in anatomical presentation, stage, treatment, and survival. We evaluated clinical characteristics, treatment patterns, and survival, with particular emphasis on whether anatomical site independently predicted overall survival (OS). Methods: We retrospectively reviewed 240 adults with histologically confirmed LMS diagnosed between January 2015 and May 2026. OS was calculated from diagnosis to death or last contact, with administrative censoring on 1 July 2026. Kaplan–Meier and Cox proportional-hazards methods were used to evaluate age, sex, anatomical site, histologic grade, and disease stage. Multivariable models adjusted for age, sex, grade, and stage assessed the independent association of anatomical site with OS. Results: Median age was 56 years, and 152 patients (63.3%) were female. Disease was localized in 120 (50.0%), de novo metastatic in 53 (22.1%), recurrent metastatic in 35 (14.6%), and recurrent localized in 12 (5.0%). Median OS was 37.0 months. Localized disease was associated with substantially longer OS than metastatic disease (61.0 vs. 13.0 months; p < 0.001). Grade 3 disease was associated with shorter OS than grade 1/2 disease (25.6 vs. 61.1 months; p < 0.001). In multivariable analyses, metastatic disease remained strongly associated with inferior OS (HR, 5.59–5.94; p < 0.001), as did age ≥ 50 years (HR, 1.86–1.92; p = 0.006–0.004) and grade 3 histology (HR, 1.74–1.92; p = 0.018–0.007). Anatomical site was not independently associated with OS (extremity/trunk vs. non-extremity: HR, 1.60; p = 0.063; non-uterine vs. uterine: HR, 1.23; p = 0.41). Conclusions: Disease stage was the strongest prognostic factor, while older age and grade 3 histology were independently associated with poorer OS. Although extremity/trunk LMS showed better univariable survival, anatomical site was not independently associated with OS after adjustment.
- Open Access
- 22 September 2026
- Published by MDPI AG in Preprints.org
Clinical Heterogeneity and Survival Disparities in Leiomyosarcoma: An Exploratory Single-Center Retrospective Observational Study
Background: Leiomyosarcoma (LMS) is a rare aggressive sarcoma with substantial heterogeneity in anatomical presentation, stage, treatment, and survival. We evaluated clinical characteristics, treatment patterns, and survival, with particular emphasis on whether anatomical site independently predicted overall survival (OS). Methods: We retrospectively reviewed 240 adults with histologically confirmed LMS diagnosed between January 2015 and May 2026. OS was calculated from diagnosis to death or last contact, with administrative censoring on July 1, 2026. Kaplan–Meier and Cox proportional-hazards methods were used to evaluate age, sex, anatomical site, histologic grade, and disease stage. Multivariable models adjusted for age, sex, grade, and stage assessed the independent association of anatomical site with OS. Results: Median age was 56 years, and 152 patients (63.3%) were female. Disease was localized in 120 (50.0%), de novo metastatic in 53 (22.1%), recurrent metastatic in 35 (14.6%), and recurrent localized in 12 (5.0%). Median OS was 37.0 months. Localized disease was associated with substantially longer OS than metastatic disease (61.0 vs 13.0 months; P<.001). Grade 3 disease was associated with shorter OS than grade 1/2 disease (25.6 vs 61.1 months; P<.001). In multivariable analyses, metastatic disease remained strongly associated with inferior OS (HR, 5.59–5.94; P<.001), as did age ≥50 years (HR, 1.86–1.92; P=.006–.004) and grade 3 histology (HR, 1.74–1.92; P=.018–.007). Anatomical site was not independently associated with OS (extremity/trunk vs non-extremity: HR, 1.60; P=.063; non-uterine vs uterine: HR, 1.23; P=.41). Conclusion: Disease stage was the strongest prognostic factor, while older age and grade 3 histology were independently associated with poorer OS. Although extremity/trunk LMS showed better univariable survival, anatomical site was not independently associated with OS after adjustment.
- 22 September 2026
- Published by MDPI AG in Preprints.org
Open AccessClinical Heterogeneity and Survival Disparities in Leiomyosarcoma: An Exploratory Single-Center Retrospective Observational Study
Background: Leiomyosarcoma (LMS) is a rare aggressive sarcoma with substantial heterogeneity in anatomical presentation, stage, treatment, and survival. We evaluated clinical characteristics, treatment patterns, and survival, with particular emphasis on whether anatomical site independently predicted overall survival (OS). Methods: We retrospectively reviewed 240 adults with histologically confirmed LMS diagnosed between January 2015 and May 2026. OS was calculated from diagnosis to death or last contact, with administrative censoring on July 1, 2026. Kaplan–Meier and Cox proportional-hazards methods were used to evaluate age, sex, anatomical site, histologic grade, and disease stage. Multivariable models adjusted for age, sex, grade, and stage assessed the independent association of anatomical site with OS. Results: Median age was 56 years, and 152 patients (63.3%) were female. Disease was localized in 120 (50.0%), de novo metastatic in 53 (22.1%), recurrent metastatic in 35 (14.6%), and recurrent localized in 12 (5.0%). Median OS was 37.0 months. Localized disease was associated with substantially longer OS than metastatic disease (61.0 vs 13.0 months; P<.001). Grade 3 disease was associated with shorter OS than grade 1/2 disease (25.6 vs 61.1 months; P<.001). In multivariable analyses, metastatic disease remained strongly associated with inferior OS (HR, 5.59–5.94; P<.001), as did age ≥50 years (HR, 1.86–1.92; P=.006–.004) and grade 3 histology (HR, 1.74–1.92; P=.018–.007). Anatomical site was not independently associated with OS (extremity/trunk vs non-extremity: HR, 1.60; P=.063; non-uterine vs uterine: HR, 1.23; P=.41). Conclusion: Disease stage was the strongest prognostic factor, while older age and grade 3 histology were independently associated with poorer OS. Although extremity/trunk LMS showed better univariable survival, anatomical site was not independently associated with OS after adjustment.
- 19 February 2024
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- Vol. 74 (4) , 342-349
Development of a Study Tool to Measure Awareness of Human Papillomavirus Vaccine Among Cancer Patients and Their Intention to Recommend the Vaccine
Background Literature suggests that there is poor awareness and uptake of the Human Papillomavirus (HPV) vaccine in India. The role of cancer patients as potent advocates for HPV vaccine in their community is vital due to their first-hand experience with the turmoil that accompanies cancer. Hence, we have developed a study tool to measure the psychometric constructs “Awareness” of HPV vaccine among cancer patients and “Intention” to recommend the vaccine. Methods The theoretical concepts of the Health Belief Model were applied, feedback from oncologists at Basavatarakam Indo-American Cancer Hospital and Research Institute and public health experts at Indian Institute of Public Health to develop the study tool. A 24 items study tool was finalized following pre-testing and content validation. A sample size of 5:1 (participant:item) was considered adequate to conduct exploratory factor analysis (EFA). The pilot study tool was administered for validation to 150 cancer patients visiting the hospital during June–July 2023. The data were analysed using Jamovi (Version2.3). Results The McDonald’s omega was 0.8, which indicates good internal consistency of the data. EFA using parallel analysis with maximum likelihood extraction method and Promax oblique rotation with factor loadings above 0.4 revealed a 3-factor solution with 21 items. Factors were named “Capability”, “Awareness” and “Risk perception” respectively. The correlation between “Awareness” and “Risk Perception” was 0.28; between “Capability” and “Risk perception” 0.47. “Awareness” and “Capability” had a weak negative correlation(-0.02). Conclusions The study tool could effectively measure individual constructs of awareness and intention. Notably, our findings indicate a weak correlation between awareness and one component of intention (capability), within this population. This aspect, rigorously measured and validated by our study tool, holds significance as it implies that despite a low level of awareness in this population, they may still be considered as potentially influential advocates for the HPV vaccine.
- 19 February 2024
- Published by Springer Nature in The Journal of Obstetrics and Gynecology of India
- Vol. 74 (4) , 342-349
Development of a Study Tool to Measure Awareness of Human Papillomavirus Vaccine Among Cancer Patients and Their Intention to Recommend the Vaccine
Background Literature suggests that there is poor awareness and uptake of the Human Papillomavirus (HPV) vaccine in India. The role of cancer patients as potent advocates for HPV vaccine in their community is vital due to their first-hand experience with the turmoil that accompanies cancer. Hence, we have developed a study tool to measure the psychometric constructs “Awareness” of HPV vaccine among cancer patients and “Intention” to recommend the vaccine. Methods The theoretical concepts of the Health Belief Model were applied, feedback from oncologists at Basavatarakam Indo-American Cancer Hospital and Research Institute and public health experts at Indian Institute of Public Health to develop the study tool. A 24 items study tool was finalized following pre-testing and content validation. A sample size of 5:1 (participant:item) was considered adequate to conduct exploratory factor analysis (EFA). The pilot study tool was administered for validation to 150 cancer patients visiting the hospital during June–July 2023. The data were analysed using Jamovi (Version2.3). Results The McDonald’s omega was 0.8, which indicates good internal consistency of the data. EFA using parallel analysis with maximum likelihood extraction method and Promax oblique rotation with factor loadings above 0.4 revealed a 3-factor solution with 21 items. Factors were named “Capability”, “Awareness” and “Risk perception” respectively. The correlation between “Awareness” and “Risk Perception” was 0.28; between “Capability” and “Risk perception” 0.47. “Awareness” and “Capability” had a weak negative correlation(-0.02). Conclusions The study tool could effectively measure individual constructs of awareness and intention. Notably, our findings indicate a weak correlation between awareness and one component of intention (capability), within this population. This aspect, rigorously measured and validated by our study tool, holds significance as it implies that despite a low level of awareness in this population, they may still be considered as potentially influential advocates for the HPV vaccine.
- 27 August 2016
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 8 (2) , 234-239
Rare Case Report of Alveolar Soft Part Sarcoma of the Orbit
Alveolar soft part sarcoma (ASPS) is a rare but distinct soft tissue tumor with unique histopathological and electron microscopic features. Orbital involvement is rare with only few reports published in the literature. ASPS have an indolent clinical course, but it is known to metastasize. Primary modality of treatment is surgery followed by adjuvant treatment. This case is a unique presentation with orbital mass with on and off bleeding. This is the largest orbital ASPS for which orbital exenteration was performed.
- 27 August 2016
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 8 (2) , 234-239
Rare Case Report of Alveolar Soft Part Sarcoma of the Orbit
Alveolar soft part sarcoma (ASPS) is a rare but distinct soft tissue tumor with unique histopathological and electron microscopic features. Orbital involvement is rare with only few reports published in the literature. ASPS have an indolent clinical course, but it is known to metastasize. Primary modality of treatment is surgery followed by adjuvant treatment. This case is a unique presentation with orbital mass with on and off bleeding. This is the largest orbital ASPS for which orbital exenteration was performed.